文献速递产科

瑞典人群研究:FMF早产子痫前期风险评估与阿司匹林预防未降低患病率

Early risk assessment and aspirin prophylaxis did not reduce preterm preeclampsia in Sweden: a population-based study.
PubMed 文献 · Am J Obstet Gynecol · 2025-10-24

这项瑞典基于人群的回顾性队列研究纳入2012至2022年5个产科单位61840例分娩,比较Fetal Medicine Foundation方法实施前后早产子痫前期患病率。意向治疗分析显示,早产子痫前期患病率无显著下降(校正OR 1.13,95%CI 0.9-1.5)。该方法在85%以上孕妇中成功实施,提示其临床可行但预防效果需进一步按方案分析评估。

要点

  • FMF方法在瑞典非选择人群中可行性良好,覆盖超过85%孕妇。
  • 意向治疗分析未显示早产子痫前期患病率显著降低。
  • 足月子痫前期患病率有升高趋势(校正OR 1.14,95%CI 1.00-1.30)。

核心结论

  • FMF方法实施后早产合并子痫前期的发生率在意向治疗分析中无下降。
  • FMF方法在非选择人群中可行且接受度良好,适用于常规临床实践。

研究设计与样本

  • 基于人群的回顾性队列研究,纳入瑞典5个产科单位2012至2022年61840例分娩。
  • 分为FMF方法实施前与实施后两个队列,干预队列30777例女性,采用意向治疗分析。
  • 风险评分≥1:100判定为高风险,推荐每日150mg阿司匹林至孕36周或子痫前期发生。

主要发现

  • 早产子痫前期患病率无显著降低,校正比值比1.13,95%置信区间0.9-1.5。
  • 足月子痫前期有升高趋势,校正比值比1.14,95%置信区间1.00-1.30。
  • 各队列间其他产科或新生儿结局无差异(P值均不显著)。
  • FMF方法在超过85%的孕妇中成功实施。

关键数值与推荐

  • 早产子痫前期定义为早产合并子痫前期诊断。
  • 高风险阈值为风险评分≥1:100。
  • 阿司匹林推荐剂量为每日150mg,持续至孕36周或子痫前期发生。

临床怎么用

  • FMF方法可作为常规临床实践中子痫前期风险分层的可行工具。
  • 该人群中FMF联合阿司匹林未显示降低早产子痫前期,需谨慎解读预防效果。

局限性

  • 为意向治疗分析,未按实际用药情况评估阿司匹林预防效力。
  • 回顾性队列设计可能存在未测量的混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preeclampsia is a substantial cause of maternal and perinatal morbimortality, with complications becoming more severe the earlier it manifests during pregnancy. The Fetal Medicine Foundation has developed a method that combines anamnestic risk factors and biochemical and biophysical tests to assess the individual risk of developing preterm preeclampsia. Previous studies have demonstrated that the combination of the Fetal Medicine Foundation method with the use of aspirin significantly reduces the prevalence of preterm preeclampsia. To our knowledge, no published studies have applied this method to an entire population before. OBJECTIVE: To evaluate the prevalence of preterm preeclampsia, defined as preterm birth with a preeclampsia diagnosis, before and after the Fetal Medicine Foundation method was introduced in an unselected Swedish population. STUDY DESIGN: This population-based, retrospective cohort study included 61,840 deliveries from 5 obstetric units in Sweden from 2012 to 2022. Two cohorts were defined: one before and one after the implementation of the Fetal Medicine Foundation method. The primary outcome was the prevalence of preterm preeclampsia. The analysis followed an intention-to-treat approach. The intervention cohort comprised 30,777 women. Individuals with a risk score of ≥1:100 were considered high risk and were subsequently recommended a daily dose of 150 mg of aspirin until 36 weeks of gestation or until the onset of preeclampsia. RESULTS: No significant reduction in the prevalence of preterm preeclampsia was observed (adjusted odds ratio, 1.13; 95% confidence interval, 0.9-1.5) but a tendency toward an increase in term preeclampsia rates was noted (adjusted odds ratio, 1.14; 95% confidence interval, 1.00-1.30). No other differences in obstetrical or neonatal outcomes were found between the cohorts (P=not significant, not significant). The Fetal Medicine Foundation method was successfully conducted in more than 85% of the pregnant population. CONCLUSION: The implementation of the Fetal Medicine Foundation method showed no reduction in preterm birth combined with preeclampsia in this intention-to-treat analysis. The Fetal Medicine Foundation method was both feasible and well accepted in this unselected population, demonstrating its applicability in routine clinical practice. Further population-based studies using a per-protocol approach are needed to evaluate the efficacy of aspirin prophylaxis among individuals identified as high risk according to the Fetal Medicine Foundation method.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Mans-Gallart, Carlhäll, Hildebrand, et al. Early risk assessment and aspirin prophylaxis did not reduce preterm preeclampsia in Sweden: a population-based study. Am J Obstet Gynecol. 2025. PMID: 41642697. doi:10.1016/j.ajog.2025.10.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。